Skip to main content

Table 1 Patient Characteristics

From: Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

 

NR

CVac

SOC

(N = 7)

(N = 29)

(N = 27)

Age, years

 Mean (SD)

52.4 (10.3)

56.8 (8.5)

56.2 (9.5)

 Median (min, max)

49 (43–70)

58 (34–75)

55 (40-74)

Race, n (%)

 White

7 (100.0 %)

26 (89.7 %)

23 (85.2 %)

 Asian

0

3 (10.3 %)

2 (7.4 %)

 Black or African American

0

0

2 (7.4 %)

Ethnicity, n (%)

 Hispanic or Latino

0

0

1 (3.8 %)

 Not Hispanic or Latino

7 (100.0 %)

29 (100.0 %)

25 (96.2 %)

Cancer stage at enrollment, n (%)

 III

5 (71 %)

24 (83 %)

20 (74 %)

 IV

2 (29 %)

5 (17 %)

7 (26 %)

Histology, n (%)

 Serous

5 (71 %)

25 (86 %)

23 (85 %)

 Clear cell

1 (14 %)

0

0

 Endometrioid

0

1 (3 %)

2 (7 %)

 Mixed, serous

0

1 (3 %)

0

 Mucinous

0

1 (3 %)

1 (4 %)

 Other

1 (14 %)a

0

0

 Other, mixed

0

1 (3 %)b

1 (4 %)c

Cytoreductive Surgery

 Optimal

7 (100 %)

26 (90 %)

21 (78 %)

 Sub-optimal

0 (0 %)

3 (10 %)

6 (22 %)

  1. aAdenocarcinoma, Primary Mullerian carcinoma
  2. bLeft ovary high grade adenocarcinoma with mixed clear cell and serous features
  3. cOvarian Adenocarcinoma, Mixed Serous & Transitional cell type Grade 3: solid & focally papillary